Skip to main content
HR 7324 115th Congress House

Preserving Access to Orphan Drugs Act of 2018

Official title: To clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers, and for other purposes.

Introduced: December 17, 2018 Introduced by: Kelly, Mike Republican · Pennsylvania See on congress.gov
Health Drug safety, medical device, and laboratory regulationDrug therapyHealth care coverage and accessPrescription drugsUser charges and fees
Sign in to write a letter Sign in to watch
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jan 2, 2019
Referred to the Subcommittee on Health.
Dec 17, 2018
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Dec 17, 2018
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action January 2, 2019

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Preserving Access to Orphan Drugs Act of 2018

This bill amends the Patient Protection and Affordable Care Act to expand the definition of orphan drug for purposes of the annual fee paid by brand name prescription drug manufacturers and importers to include medications for rare conditions that were, prior to 2011, approved or in clinical trials. (Drug manufacturers and importers pay an annual fee based on their sales of brand name prescription drugs, excluding sales of orphan drugs.)

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 3
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 7324: Preserving Access to Orphan Drugs Act of 2018. 115th Congress. Open America. https://openamerica.io/bill/115-HR-7324/
MLA
"H.R. 7324: Preserving Access to Orphan Drugs Act of 2018." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-7324/.
Bluebook (legal)
H.R. 7324, 115th Cong. (2026), https://openamerica.io/bill/115-HR-7324/.
Markdown link
[H.R. 7324: Preserving Access to Orphan Drugs Act of 2018](https://openamerica.io/bill/115-HR-7324/)
Report a problem